Thursday, September 30, 2004 8:26:33 AM
Regarding the test you two were just referring to.....
What is your opinion regarding the previous Orchid (now Bechman) contract, with DNAP now going to be majority owner of Biofrontera?
Do you think DNAP could now just let Biofrontera "know" their platform, and reap the benefits of being a pharma through being majority owner of them??
I've been curious as to how this will be managed. Of course if I remember correctly, there was a 6 month stipulation in that contract, and it was specific to non DNAP generated products.
Have a nice day
66fan
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM